BC
PTCT icon

Bayforest Capital’s PTC Therapeutics PTCT Stock Holding History

Bayforest Capital’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-18,779
Closed -$917K – 886
2025
Q2 		$917K Buy
18,779
+10,626
+130% +$504K 0.4% 51
2025
Q1 		$415K Buy
+8,153
New +$407K 0.18% 205

Other funds holding PTCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bayforest Capital's PTCT Position: Q3 2025 in Review

Bayforest Capital sold out of PTC Therapeutics (PTCT) in Q3 2025, closing a stake of 18,779 shares — an estimated $917K sold.

Bayforest Capital first reported a position in PTCT in Q1 2025 and held it in 2 quarters. The position peaked at $917K in Q2 2025. 293 funds tracked by Wall St. Rank hold PTCT as of Q3 2025.

  • Bayforest Capital reported no remaining PTC Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Bayforest Capital sold 18,779 PTC Therapeutics shares in Q3 2025, an estimated $917K.
  • Bayforest Capital first reported a position in PTC Therapeutics in Q1 2025 and held it in 2 quarters.
  • Bayforest Capital's PTC Therapeutics position peaked at $917K in Q2 2025.
  • 293 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2025.

Based on Bayforest Capital's 13F filing for Q3 2025, filed 24 Oct 2025.